PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) was down 0.1% during mid-day trading on Wednesday . The company traded as low as $0.97 and last traded at $0.97. Approximately 29,206 shares changed hands during trading, an increase of 231% from the average daily volume of 8,831 shares. The stock had previously closed at $0.97.
PharmaCyte Biotech Stock Performance
The business’s 50-day moving average is $0.97 and its 200-day moving average is $1.10.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Featured Articles
- Five stocks we like better than PharmaCyte Biotech
- How to Short a Stock in 5 Easy Steps
- Datavault AI: The New AI Contender Backed by Big Funding
- 3 Fintech Stocks With Good 2021 Prospects
- CoreWeave: Why the New King of AI Infrastructure Has Room to Run
- What is an Earnings Surprise?
- Top 3 Dividend Achievers for October: High Yields, Growth Ahead
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
